Avalo Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AVTX and other ETFs, options, and stocks.About AVTX
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders.
CEOGarry Arthur Neil
CEOGarry Arthur Neil
Employees23
Employees23
HeadquartersWayne, Pennsylvania
HeadquartersWayne, Pennsylvania
Founded2011
Founded2011
Employees23
Employees23
AVTX Key Statistics
Market cap275.27M
Market cap275.27M
Price-Earnings ratio-1.73
Price-Earnings ratio-1.73
Dividend yield—
Dividend yield—
Average volume385.14K
Average volume385.14K
High today$15.61
High today$15.61
Low today$14.01
Low today$14.01
Open price$14.30
Open price$14.30
Volume521.51K
Volume521.51K
52 Week high$19.41
52 Week high$19.41
52 Week low$3.39
52 Week low$3.39
Stock Snapshot
With a market cap of 275.27M, Avalo Therapeutics(AVTX) trades at $15.43. The stock has a price-to-earnings ratio of -1.73.
On 2025-11-15, Avalo Therapeutics(AVTX) stock moved within a range of $14.01 to $15.61. With shares now at $15.43, the stock is trading +10.1% above its intraday low and -1.2% below the session's peak.
Trading volume for Avalo Therapeutics(AVTX) stock has reached 521.51K, versus its average volume of 385.14K.
Over the past 52 weeks, Avalo Therapeutics(AVTX) stock has traded between a high of $19.41 and a low of $3.39.
Over the past 52 weeks, Avalo Therapeutics(AVTX) stock has traded between a high of $19.41 and a low of $3.39.
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own AVTX. This list is generated using Robinhood data, and it’s not a recommendation.